We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 103% below its sector, cheaper than its peers on earnings.
Aptahem AB (publ) is a clinical-stage biotechnology company dedicated to creating aptamer-based pharmaceuticals aimed at treating acute, life-threatening medical conditions. Its flagship drug candidate, Apta-1, is currently in preclinical development, designed to reduce the mortality rate in sepsis patients by combating organ and tissue damage. The company has established partnerships with several academic institutions, notably through a consortium comprising Örebro University, Seattle Children's Research Institute, and University Health Network. Founded in 2014, Aptahem AB (publ) operates from its headquarters in Malmö, Sweden.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save APTA.ST and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
